# About CJC-1295 Store: An Independent Research Digest

> CJC-1295 Store is an independent editorial project that publishes plain-language summaries of the peer-reviewed CJC-1295 research literature. Not a clinic, not a vendor, not a prescription.

An independent editorial project that reads the published CJC-1295 record straight — and says where it stops.

## What this site is

CJC-1295 Store is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The project exists because the CJC-1295 literature is small, technical, and badly served online — the DAC and no-DAC forms are constantly conflated, early pharmacokinetic data get treated as efficacy data, and the one approved analog in the class rarely gets used as a benchmark. This digest maps the record as the process it describes: a looping GH/IGF-1 axis, a development arc from native GHRH(1-29) to a long-acting lead, and a comparison to tesamorelin that keeps the evidence tiers honest.

## About the name

The word "store" in this domain is editorial framing, not a description of services. Nothing is stocked, listed, priced, or sold here. The name is a position the publisher occupies relative to the literature — a place where the CJC-1295 research record is gathered and organized — not a claim that the site offers a product, a consultation, or a prescription.

We hold to a few rules. Every quantitative claim cites a study or registry on the [full reference list](/references). Doses are reported as what was administered to which species by which route, never as a recommendation. We use generic compound names only. And where the literature is silent — on long-term safety, on controlled efficacy, on a validated human dose — we say so plainly rather than filling the gap.

## How the digest is built

The content is organized around the structure of the evidence. The mechanism and the GH/IGF-1 kinetics live on the [research page](/research). The doses that appear in studies live on the dosage page. The two comparisons that matter most — against the approved analog, and between the DAC and no-DAC variants — each get a dedicated page. Findings are tagged by the strength of evidence behind them, so a Phase 3 trial result and an early pharmacokinetic readout are never presented as equals. This is a reading of the science, not a course of treatment.

## Editorial standards

Three standards govern what appears here. First, every quantitative claim resolves to a study or registry: the 5.8-8.1-day half-life to the human pharmacokinetic work [1], the four-fold GH area-under-the-curve to the discovery paper [2], the tesamorelin visceral-fat results to the Phase 3 trials [7][8]. A figure without a source does not go on the page.

Second, evidence is reported at its true weight. CJC-1295's human record is early-phase pharmacokinetics; tesamorelin's is randomized controlled trials. We never let the shared mechanism blur that gap, and we mark the absence of controlled efficacy and long-term safety data as plainly as we mark the data that exists.

Third, we report disagreement rather than resolving it by fiat. Where chemical registries differ on CJC-1295's molecular formula, the digest says so and flags the value for confirmation [2]. The goal is a reader who can check every line — which is why the [references page](/references) carries DOIs and PubMed identifiers for each source, paywalled or not.

---

A corporate process deck mapping the CJC-1295 record phase by phase — the GH and IGF-1 kinetics logged to source, the DAC-versus-no-DAC split kept apart, and the missing efficacy and long-term safety data marked, not filled; no clinic behind the deck and nothing here listed, priced, or sold.